Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (22.04.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 22.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
Stammdaten
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Unternehmen & Branche
| Name | AMGEN INC |
|---|---|
| Ticker | AMGN |
| CIK | 0000318154 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - General |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 031162100 |
|---|---|
| ISIN | US0311621009 |
| Typ | Common Stock |
| Marktkapitalisierung | 188,75 Mrd. USD |
| Beta | 0,47 |
| Dividendenrendite | 9,66 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 36,751,000,000 | 7,711,000,000 | 14.23 | 90,586,000,000 | 8,658,000,000 |
| 2025-09-30 | 10-Q | 9,557,000,000 | 3,216,000,000 | 5.93 | 90,141,000,000 | 9,619,000,000 |
| 2025-06-30 | 10-Q | 9,179,000,000 | 1,432,000,000 | 2.65 | 87,897,000,000 | 7,428,000,000 |
| 2025-03-31 | 10-Q | 8,149,000,000 | 1,730,000,000 | 3.20 | 89,367,000,000 | 6,207,000,000 |
| 2024-12-31 | 10-K | 33,424,000,000 | 4,090,000,000 | 7.56 | 91,839,000,000 | 5,877,000,000 |
| 2024-09-30 | 10-Q | 8,503,000,000 | 2,830,000,000 | 5.22 | 90,883,000,000 | 7,527,000,000 |
| 2024-06-30 | 10-Q | 8,388,000,000 | 746,000,000 | 1.38 | 90,907,000,000 | 5,925,000,000 |
| 2024-03-31 | 10-Q | 7,447,000,000 | -113,000,000 | -0.21 | 92,980,000,000 | 5,022,000,000 |
| 2023-12-31 | 10-K | 28,190,000,000 | 6,717,000,000 | 12.49 | 97,154,000,000 | 6,232,000,000 |
| 2023-09-30 | 10-Q | 6,903,000,000 | 1,730,000,000 | 3.22 | 90,534,000,000 | 7,656,000,000 |
| 2023-06-30 | 10-Q | 6,986,000,000 | 1,379,000,000 | 2.57 | 90,269,000,000 | 6,781,000,000 |
| 2023-03-31 | 10-Q | 6,105,000,000 | 2,841,000,000 | 5.28 | 88,720,000,000 | 5,348,000,000 |
| 2022-12-31 | 10-K | 26,323,000,000 | 6,552,000,000 | 12.11 | 65,121,000,000 | 3,661,000,000 |
| 2022-09-30 | 10-Q | 6,652,000,000 | 2,143,000,000 | 3.98 | 63,700,000,000 | 3,653,000,000 |
| 2022-06-30 | 10-Q | 6,594,000,000 | 1,317,000,000 | 2.45 | 59,294,000,000 | 2,419,000,000 |
| 2022-03-31 | 10-Q | 6,238,000,000 | 1,476,000,000 | 2.68 | 59,196,000,000 | 916,000,000 |
| 2021-12-31 | 10-K | 25,979,000,000 | 5,893,000,000 | 10.28 | 61,165,000,000 | 6,700,000,000 |
| 2021-09-30 | 10-Q | 6,706,000,000 | 1,884,000,000 | 3.31 | 64,993,000,000 | 8,217,000,000 |
| 2021-06-30 | 10-Q | 6,526,000,000 | 464,000,000 | 0.81 | 59,773,000,000 | 8,247,000,000 |
| 2021-03-31 | 10-Q | 5,901,000,000 | 1,646,000,000 | 2.83 | 62,539,000,000 | 9,334,000,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 54,838,826 | 0 | 54,838,826 | 17,949,296,138 | Neu | +100,0% | |
| BlackRock, Inc. | 47,396,138 | 0 | 47,396,138 | 15,513,229,833 | Neu | +100,0% | |
| STATE STREET CORP | 30,591,403 | 0 | 30,591,403 | 10,012,872,116 | Neu | +100,0% | |
| Capital World Investors | 23,097,711 | 0 | 23,097,711 | 7,560,249,344 | Neu | +100,0% | |
| Capital International Investors | 18,186,270 | 0 | 18,186,270 | 5,952,964,722 | Neu | +100,0% | |
| MORGAN STANLEY | 15,744,528 | 0 | 15,744,528 | 5,153,342,607 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 14,303,294 | 0 | 14,303,294 | 4,665,822,333 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 11,811,045 | 0 | 11,811,045 | 3,865,873,139 | Neu | +100,0% | |
| PRIMECAP MANAGEMENT CO/CA/ | 8,904,979 | 0 | 8,904,979 | 2,914,688,677 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 7,112,793 | 0 | 7,112,793 | 2,328,088,092 | Neu | +100,0% | |
| NORGES BANK | 6,611,965 | 0 | 6,611,965 | 2,164,162,264 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 6,181,658 | 0 | 6,181,658 | 2,023,318,481 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 5,537,361 | 0 | 5,537,361 | 1,812,433,488 | Neu | +100,0% | |
| Invesco Ltd. | 4,788,460 | 0 | 4,788,460 | 1,567,310,831 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 4,706,930 | 0 | 4,706,930 | 1,540,624,000 | Neu | +100,0% | |
| Capital Research Global Investors | 4,648,155 | 0 | 4,648,155 | 1,521,390,119 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 4,604,019 | 0 | 4,604,019 | 1,506,941,458 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 4,600,358 | 0 | 4,600,358 | 1,505,743,070 | Neu | +100,0% | |
| UBS Group AG | 4,179,912 | 0 | 4,179,912 | 1,368,126,997 | Neu | +100,0% | |
| Legal & General Group Plc | 3,811,451 | 0 | 3,811,451 | 1,247,526,029 | Neu | +100,0% | |
| FMR LLC | 3,592,220 | 0 | 3,592,220 | 1,175,769,605 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 3,230,979 | 0 | 3,230,979 | 1,057,561,123 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 3,157,971 | 0 | 3,157,971 | 1,033,635,488 | Neu | +100,0% | |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 2,715,656 | 0 | 2,715,656 | 888,861,365 | Neu | +100,0% | |
| NORDEA INVESTMENT MANAGEMENT AB | 2,601,135 | 0 | 2,601,135 | 851,923,735 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 2,383,625 | 0 | 2,383,625 | 780,184,839 | Neu | +100,0% | |
| JANUS HENDERSON GROUP PLC | 2,322,793 | 0 | 2,322,793 | 760,300,163 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 2,190,809 | 0 | 2,190,809 | 717,073,696 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2,175,586 | 0 | 2,175,586 | 712,090,715 | Neu | +100,0% | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 2,087,589 | 0 | 2,087,589 | 683,288,756 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 2,027,224 | 0 | 2,027,224 | 664,118,958 | Neu | +100,0% | |
| BARCLAYS PLC | 1,960,895 | 0 | 1,960,895 | 641,820,541 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1,703,580 | 0 | 1,703,580 | 557,598,770 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 1,702,750 | 0 | 1,702,750 | 557,337,017 | Neu | +100,0% | |
| STIFEL FINANCIAL CORP | 1,594,369 | 0 | 1,594,369 | 521,896,977 | Neu | +100,0% | |
| HSBC HOLDINGS PLC | 1,537,251 | 0 | 1,537,251 | 503,569,862 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 1,504,889 | 0 | 1,504,889 | 492,565,219 | Neu | +100,0% | |
| Swiss National Bank | 1,475,273 | 0 | 1,475,273 | 482,871,606 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 1,121,318 | 0 | 1,121,318 | 412,318,953 | Neu | +100,0% | |
| National Pension Service | 1,239,549 | 0 | 1,239,549 | 405,716,783 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 1,192,290 | 0 | 1,192,290 | 390,248,440 | Neu | +100,0% | |
| LPL Financial LLC | 1,183,152 | 0 | 1,183,152 | 387,257,499 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 1,137,313 | 0 | 1,137,313 | 372,253,918 | Neu | +100,0% | |
| CITIGROUP INC | 1,129,703 | 0 | 1,129,703 | 369,763,232 | Neu | +100,0% | |
| BANK OF MONTREAL /CAN/ | 1,088,220 | 0 | 1,088,220 | 356,185,163 | Neu | +100,0% | |
| ProShare Advisors LLC | 1,073,105 | 0 | 1,073,105 | 351,237,998 | Neu | +100,0% | |
| RHUMBLINE ADVISERS | 931,065 | 0 | 931,065 | 304,746,775 | Neu | +100,0% | |
| Fisher Asset Management, LLC | 903,557 | 0 | 903,557 | 295,743,740 | Neu | +100,0% | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 845,056 | 0 | 845,056 | 276,595,279 | Neu | +100,0% | |
| Marex Group plc | 801,362 | 0 | 801,362 | 262,293,797 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | Santos Esteban | Officer, EVP, Operations | Open Market Sale | -30,501 | 379.12 | -11,563,456.77 | -446,2% | |
| 2026-02-26 | Santos Esteban | Officer, EVP, Operations | Open Market Sale | -24,291 | 379.12 | -9,209,138.33 | -355,4% | |
| 2026-02-19 | Busch Matthew C. | Officer, VP, Finance & CAO | Open Market Sale | -1,000 | 375.79 | -375,790.00 | -14,5% | |
| 2025-11-20 | Grygiel Nancy A. | Officer, SVP & CCO | Open Market Sale | -1,500 | 337.26 | -505,893.75 | -19,5% | |
| 2025-11-20 | Grygiel Nancy A. | Officer, SVP & CCO | Open Market Sale | -1,639 | 337.26 | -552,773.24 | -21,3% | |
| 2025-11-12 | Khosla Rachna | Officer, SVP, Business Development | Open Market Sale | -890 | 336.24 | -299,255.56 | -11,5% | |
| 2025-11-12 | Gordon Murdo | Officer, EVP, Global Commercial Ops | Open Market Sale | -6,879 | 336.83 | -2,317,071.46 | -89,4% | |
| 2025-08-20 | Grygiel Nancy A. | Officer, SVP & CCO | Open Market Sale | -1,267 | 296.99 | -376,280.00 | -14,5% | |
| 2025-06-05 | Khosla Rachna | Officer, SVP, Business Development | Open Market Sale | -1,500 | 289.68 | -434,520.00 | -16,8% | |
| 2025-05-02 | Busch Matthew C. | Officer, VP, Finance & CAO | Open Market Sale | -1,000 | 279.69 | -279,690.00 | -10,8% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-30 | 58 | 348,77 | 20.229 |
| 2026-03-27 | 1.542 | 353,16 | 544.573 |
| 2026-03-25 | 208 | 348,43 | 72.473 |
| 2026-03-24 | 63 | 349,77 | 22.036 |
| 2026-03-23 | 208.764 | 347,80 | 72.608.119 |
| 2026-03-19 | 259 | 351,48 | 91.033 |
| 2026-03-17 | 69.252 | 366,25 | 25.363.545 |
| 2026-03-13 | 28 | 367,79 | 10.298 |
| 2026-03-12 | 36.071 | 377,64 | 13.621.852 |
| 2026-03-09 | 19.437 | 369,53 | 7.182.555 |
| 2026-03-04 | 76.913 | 377,00 | 28.996.201 |
| 2026-03-02 | 13 | 388,16 | 5.046 |
| 2026-02-24 | 83 | 379,42 | 31.492 |
| 2026-02-23 | 47.448 | 374,75 | 17.781.138 |
| 2026-02-20 | 16.569 | 375,50 | 6.221.660 |
| 2026-02-17 | 20.993 | 369,19 | 7.750.406 |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| OPPENHEIMER & CO INC | 119,841 | 42,166,056 | 58.18 |
| AVITY INVESTMENT MANAGEMENT INC. | 72,379 | 25,466,551 | 35.14 |
| PW Nova Financial Services LLC | 5,172 | 1,819,731 | 2.51 |
| MANCHESTER FINANCIAL INC | 4,030 | 1,417,951 | 1.96 |
| HARTLINE INVESTMENT CORP/ | 3,006 | 1,057,661 | 1.46 |
| Capital Investment Management, Inc. | 800 | 281,480 | 0.39 |
| West Financial Advisors, LLC | 764 | 268,814 | 0.37 |